Mr. Tianhao Zou | Cancer Immunotherapy | Best Researcher Award

Tongji Medical College Huazhong University of Science and Technology | China

Author Profile

🌟Dr. Tianhao Zou: A Rising Star in Hepatobiliary Oncology 🌟

Full Name: Tianhao Zou
Gender: Male
Designation: Resident Physician
Department: Department of Hepatobiliary Surgery, Center for Liver Transplantation
Institution/Organization: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
Qualification: Doctor
Area of Specialization: Hepatobiliary Oncology and Cancer
Sub Division: Oncology Therapeutics and Novel Approaches
DOB: September 10, 1997
DOJ: July 01, 2021
Total Experience: Doctor for 1 year, Master for 3 years, Bachelor for 5 years
Mobile Number: +86 18162279089
Email: zoutianhao@126.co

📚 Education:

2015-2020: Bachelor of Clinical Medicine, School of Medicine of Nanchang University.
2020-2023: Master of Surgery, Tongji Medical College, Huazhong University of Science and Technology.
2023-present: Doctor of Surgery, Tongji Medical College, Huazhong University of Science and Technology.

🔬 Experience:

July 2021 to present: Resident Physician, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

🏅 Research, Innovations, and Extensions:

No. of Research Projects Completed and Ongoing: 6
Citation Index: 61
Consultancy and Industry Sponsored Projects: 0
Books Published with ISBN: 0
Total Cost of Projects: $414,000 USD
Patents Published and Under Process: 5
Journals Published in SCI and SCIE Index: 12
Editorial Appointments in Journals/Conferences: 2
Journals Published in Scopus, Web of Science, and PubMed Index: 13
Countries Visited for Research Activities: 1
Journals Published in Other Index: 4
Research Scholars Graduated: 0
Conference Presentations: 0
Research Scholars Ongoing: 0
Cumulative Impact Factor (Last 3 Years): 55
Invited Speaker/Resource Person: 1
H-index: 5
Research Conferences/Workshops Organized: 0
Collaborative Activities for Research: 0
Awards and Recognition Received: 1
Functional MoUs with Other Universities/Industries/Corporates: 0
Membership in Professional Bodies: 10

🌟 Areas of Research:

Oncology Therapeutics and Novel Approaches

Contributions to Research & Development, Innovations, and Extension Activities:

Dr. Tianhao Zou has made substantial contributions to the field of tumor research, particularly focusing on hepatobiliary malignancies. His active participation in research projects has significantly advanced the understanding of tumor biology, therapeutic interventions, and patient care outcomes. By collaborating with interdisciplinary teams, Dr. Zou has identified novel biomarkers, therapeutic targets, and treatment modalities aimed at improving patient outcomes and quality of life.

In his innovative efforts, Dr. Zou has played a pivotal role in translating research findings into clinical practice. His collaborations with industry stakeholders, academic institutions, and healthcare providers have facilitated the development and implementation of cutting-edge technologies and treatment approaches in oncology.

Beyond his research endeavors, Dr. Zou is committed to extension activities that promote cancer prevention, early detection, and treatment within the community. Through educational workshops, public seminars, and outreach programs, he empowers patients, caregivers, and healthcare professionals with essential information and resources to combat cancer effectively. Dr. Zou’s dedication to advancing cancer research, innovation, and community outreach underscores his commitment to making a meaningful impact in the fight against cancer.

🔗 Proof Links:

Institute ID: D202382031
Certificate (Education Proof of Last Degree): 1048732023102672
Passport/Govt. ID (Age Proof): 360425199709100212

📜✍️Declaration:

I authenticate that to the best of my knowledge, the information given in this form is correct and complete. At any time I am found to have concealed any material information, my application shall be liable to be summarily terminated without notice. I have read the terms and conditions and other policies of the International Research Awards and agree to stand by the same. I agree to Pencis to process the data submitted in this application form, or any other data that the Foundation may obtain from me for any purposes connected with Pencis for any other legitimate reason.

📊🔬Notable Publication:

Title: Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma
- Authors: Xu, J.; Zheng, Q.; Cheng, X.; Yi, X.; Gao, Y.
- Journal: Journal of Nanobiotechnology
- Volume: 19
- Issue: 1
- Pages: 355
- Year: 2021

Title: High PPT1 expression predicts poor clinical outcome and PPT1 inhibitor DC661 enhances sorafenib sensitivity in hepatocellular carcinoma
- Authors: Xu, J.; Su, Z.; Cheng, X.; Gao, Y.; Zheng, Q.
- Journal: Cancer Cell International
- Volume: 22
- Issue: 1
- Pages: 115
- Year: 2022

Title: Cell therapy for neuropathic pain
- Authors: Yin, Q.; Zou, T.; Sun, S.; Yang, D.
- Journal: Frontiers in Molecular Neuroscience
- Volume: 16
- Pages: 1119223
- Year: 2023

Title: Light-triggered polymeric prodrug and nano-assembly for chemo-photodynamic therapy and potentiate immune checkpoint blockade immunotherapy for hepatocellular carcinoma
- Authors: Gao, Y.; Su, Z.; Wang, C.; Yi, X.; Zheng, Q.
- Journal: Materials and Design
- Volume: 225
- Pages: 111457
- Year: 2023

Title: A NRF2 Regulated and the Immunosuppressive Microenvironment Reversed Nanoplatform for Cholangiocarcinoma Photodynamic-Gas Therapy
- Authors: Wang, W.; Gao, Y.; Xu, J.; Xia, Y.; Zheng, Q.
- Journal: Advanced Science
- Volume: 11
- Issue: 14
- Pages: 2307143
- Year: 2024

EARLY ACADEMIC PURSUITS

Li Hao began his academic journey at Dalian Medical University in September 2015, majoring in Immunology, Biochemistry, Surgery, and Internal Medicine. During this period from 2015 to 2020, he laid the foundational knowledge in the medical sciences that would serve as the basis for his future specialization. His undergraduate studies provided him with a comprehensive understanding of the human body's immune system, biochemistry, surgical techniques, and internal medicine.Li Hao pursued his Master's degree in Emergency Medicine and Molecular Biology at China Medical University. This advanced academic pursuit enabled him to delve deeper into specialized areas of medicine, focusing on emergency care and the molecular mechanisms underlying various medical conditions.

PROFESSIONAL ENDEAVORS

In May 2021, Li Hao started his professional career as a Resident Physician at the First Hospital of China Medical University. During his tenure from May 2021 to August 2021, he gained hands-on experience in clinical settings, honing his skills in medical records writing and cardiopulmonary resuscitation (CPR). This role allowed him to apply his theoretical knowledge from his undergraduate studies in a practical setting, preparing him for more specialized roles in the medical field.In June 2023, Li Hao transitioned to the role of an Assistant at the First Hospital of China Medical University, where he continues to work to the present day. As an Assistant, he has been involved in research projects and clinical work, further expanding his expertise and contributing to advancements in the medical field.

CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR IMMUNOLOGY

Li Hao's research interests are diverse and interdisciplinary, focusing on the areas of nanomaterials, hepatocellular carcinoma, and macrophage biology. His research aims to explore innovative approaches and treatments for these medical conditions, leveraging the latest advancements in molecular biology and emergency medicine.

IMPACT AND INFLUENCE

Li Hao's contributions to the medical field extend beyond his professional roles, as he actively engages in research and academic pursuits that have the potential to make a significant impact. His research in nanomaterials, hepatocellular carcinoma, and macrophage biology could lead to breakthroughs in treatment options and improve patient outcomes in these areas.

ACADEMIC SITES

Li Hao's academic achievements and research contributions have likely been cited in various scientific publications and conferences. His interdisciplinary research in nanomaterials, hepatocellular carcinoma, and macrophage biology demonstrates his commitment to advancing medical science and contributing valuable insights to the academic community.

LEGACY AND FUTURE CONTRIBUTIONS

As Li Hao continues to pursue his career in emergency medicine and molecular biology, his interdisciplinary research and clinical experience will undoubtedly leave a lasting legacy in the medical field. His dedication to improving patient care and advancing medical science positions him as a promising young professional with the potential to make significant contributions to the future of healthcare.